You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic nasopharyngeal carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jun 1, 2023

Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)

Recruiting
  • Nasopharyngeal Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital of Medical College
Nov 28, 2022

Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)

Not yet recruiting
  • Recurrent Metastatic Nasopharyngeal Carcinoma
  • (no location specified)
Jan 29, 2023

Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy Trial in Zhongshan (Reduction CTVp1, Non-reduction CTVp1)

Recruiting
  • Nasopharyngeal Carcinoma
  • Intensity-Modulated Radiotherapy
  • Reduction CTVp1
  • Non-reduction CTVp1
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Aug 8, 2023

Nasopharyngeal Carcinoma, Maintenance Therapy Trial in Guangzhou (Capecitabine/Placebo combined with treprizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Maintenance Therapy
  • Capecitabine/Placebo combined with treprizumab
  • Guangzhou, Guangdong, China
    SunYat-senU
May 11, 2023

Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anrotinib plus Tirelizumab
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Jul 31, 2023

Nasopharyngeal Tumors Trial (The combination treatment of anlotinib, penpulimab and capecitabine.)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • The combination treatment of anlotinib, penpulimab and capecitabine.
  • (no location specified)
Apr 10, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Advanced Nasopharyngeal Carcinoma Trial in Hangzhou (SBRT)

Recruiting
  • Advanced Nasopharyngeal Carcinoma
  • SBRT
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Dec 5, 2022

Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

Active, not recruiting
  • Recurrent Nasopharyngeal Carcinoma
  • +2 more
  • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
  • Guangzhou, Guangdong, China
    Yanqun Xiang
Sep 5, 2022

Metastatic Nasopharyngeal Carcinoma Trial (Capecitabine plus toripalimab)

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • Capecitabine plus toripalimab
  • (no location specified)
Jul 30, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Nivolumab
  • +5 more
  • (no location specified)
Aug 21, 2023

Nasopharyngeal Carcinoma Trial in Xuzhou (BGT007 Cell Injection, Fludarabine, cyclophosphamide)

Recruiting
  • Nasopharyngeal Carcinoma
  • BGT007 Cell Injection
  • +2 more
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 14, 2022

Nasopharyngeal Carcinoma Trial in China (TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride

Recruiting
  • Nasopharyngeal Carcinoma
  • TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
  • +2 more
  • Guangzhou, Guangdong, China
  • +3 more
Nov 28, 2022

Metastatic Nasopharyngeal Cancer Trial in Shenzhen (Radiotherapy)

Recruiting
  • Metastatic Nasopharyngeal Cancer
  • Radiotherapy
  • Shenzhen, China
    National Cancer Center/National Clinical Research Center for Can
May 21, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Gemcitabine combined with Aptinib and Toripalimab)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Gemcitabine combined with Aptinib and Toripalimab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 24, 2022

Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma Trial in Guangzhou (Toripalimab and Anlotinib)

Recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic Nasopharyngeal Carcinoma
  • Toripalimab and Anlotinib
  • Guangzhou, China
    Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Mar 23, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (QL1706, Carrelizumab, Gemcitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangzhou, China
    Sun Yat-sen University Cancer Center
Oct 21, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Immunotherapy+induction chemo+radiotherapy)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immunotherapy+induction chemotherapy+radiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 9, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)

Completed
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022

Nasopharyngeal Carcinoma, Leucogen, Chemo Trial in Guangzhou (5-fu, Lobaplatin, Placebo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Radiation Oncology, Sun Yat-Sen University Cancer
Mar 10, 2023

Nasopharyngeal Carcinoma Trial in Beijing, Shanghai (AK105)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • AK105
  • Beijing, Beijing, China
  • +1 more
Mar 30, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Niraparib,Sintilimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Li zhang
Dec 6, 2021

Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Recurrent or Metastatic
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Mar 23, 2022